WWW.BOOK.DISLIB.INFO
FREE ELECTRONIC LIBRARY - Books, dissertations, abstract
 
<< HOME
CONTACTS



Pages:     | 1 |   ...   | 16 | 17 || 19 | 20 |   ...   | 34 |

«2013 Annual Report breakthrough technologies and services focused on Dear Fellow Shareholders, addressing specific customer and market needs. Several ...»

-- [ Page 18 ] --

Revenue recognition. We record product revenue when persuasive evidence of an arrangement exists, delivery has occurred, the price to the buyer is fixed or determinable, and collectability is reasonably assured. For products that include installation, and if the installation meets the criteria to be considered a separate element, we recognize product revenue upon delivery, and recognition of installation revenue is recognized when the installation is complete. For revenue that includes customer-specified acceptance criteria, we recognize revenue after the acceptance criteria have been met. Certain of our products require specialized installation. Revenue for these products is deferred until installation is completed. We defer revenue from services and recognize it over the contractual period, or as services are rendered.

In limited circumstances, we have arrangements that include multiple elements that are delivered at different points of time, such as revenue from products and services with a remaining service or storage component, such as cord blood processing and storage. For these arrangements, the revenue is allocated to each of the deliverables based upon their relative selling prices as determined by a selling-price hierarchy. A deliverable in an arrangement qualifies as a separate unit of accounting if the delivered item has value to the customer on a standalone basis. A delivered item that does not qualify as a separate unit of accounting is combined with the other undelivered items in the arrangement and revenue is recognized for those combined deliverables as a single unit of accounting. The selling price used for each deliverable is based upon vendor-specific objective evidence (“VSOE”) if such evidence is available, third-party evidence (“TPE”) if VSOE is not available, and management’s best estimate of selling price (“BESP”) if neither VSOE nor TPE are available. TPE is the price of our or any competitor’s largely interchangeable products or services in stand-alone sales to similarly-situated customers. BESP is the price at which we would sell the deliverable if it were sold regularly on a stand-alone basis, considering market conditions and entity-specific factors.

Revenue from software licenses and services was 5% of our total revenue for fiscal year 2013, 3% of our total revenue for fiscal year 2012, and 2% of our total revenue for fiscal year 2011. We sell our software licenses with maintenance services and, in some cases, also with consulting services. For the undelivered elements, we determine VSOE of fair value to be the price charged when the undelivered element is sold separately. We determine VSOE for maintenance sold in connection with a software license based on the amount that was separately charged for the maintenance renewal period. We determine VSOE for consulting services by reference to the amount charged for similar engagements when a software license sale is not involved.

We recognize revenue from software licenses sold together with maintenance and/or consulting services upon shipment using the residual method, provided that the above criteria have been met. If VSOE of fair value for the undelivered elements cannot be established, we defer all revenue from the arrangement until the earlier of the point at which such sufficient VSOE does exist or all elements of the arrangement have been delivered, or if the only undelivered element is maintenance, then we recognize the entire fee ratably over the maintenance period.

The majority of our sales relate to specific manufactured products or units rather than long-term customized projects, therefore we generally do not experience significant changes in original estimates. Further, we have not experienced any significant refunds or promotional allowances that require significant estimation.

Warranty costs. We provide for estimated warranty costs for products at the time of their sale. Warranty liabilities are estimated using expected future repair costs based on historical labor and material costs incurred during the warranty period.

Allowances for doubtful accounts. We maintain allowances for doubtful accounts for estimated losses resulting from the inability of our customers to make required payments. We generally compute our allowance for doubtful accounts by (i) applying specific percentage reserves on accounts that are past due and deemed uncollectible; and (ii) specifically reserving for customers known to be in financial difficulty. Therefore, if the financial condition of our customers were to deteriorate beyond our estimates, we may have to increase our allowance for doubtful accounts. This would reduce our earnings. Accounts are written-off only when all methods of recovery have been exhausted.

Inventory valuation. We initially value inventory at actual cost to purchase and/or manufacture. We periodically review these values to ascertain that market value of the inventory continues to exceed its recorded cost. Generally, reductions in value of inventory below cost are caused by our maintenance of stocks of products in excess of demand, or technological obsolescence of the inventory. We regularly review inventory quantities on hand and, when necessary, record provisions for excess and obsolete inventory based on either our estimated forecast of product demand and production requirements, or historical trailing usage of the product. If our sales do not materialize as planned or at historic levels, we may have to increase our reserve for excess and obsolete inventory. This would reduce our earnings. If actual market conditions are more favorable than anticipated, inventory previously written down may be sold, resulting in lower costs of sales and higher income from operations than expected in that period.





Business combinations. Business combinations are accounted for at fair value. Acquisition costs are expensed as incurred and recorded in selling, general and administrative expenses; previously held equity interests are valued at fair value upon the acquisition of a controlling interest; in-process research and development (“IPR&D”) is recorded at fair value as an intangible asset at the acquisition date; restructuring costs associated with a business combination are expensed subsequent to the acquisition date; and changes in deferred tax asset valuation allowances and income tax uncertainties after the acquisition date affect income tax expense.

All changes that do not qualify as measurement period adjustments are included in current period earnings. The accounting for business combinations requires estimates and judgment as to expectations for future cash flows of the acquired business, and the allocation of those cash flows to identifiable intangible assets, in determining the estimated fair value for assets acquired and liabilities assumed. The fair values assigned to tangible and intangible assets acquired and liabilities assumed, including contingent consideration, are based on management’s estimates and assumptions, as well as other information compiled by management, including valuations that utilize customary valuation procedures and techniques. If the actual results differ from the estimates and judgments used in these estimates, the amounts recorded in the financial statements could result in a possible impairment of the intangible assets and goodwill, require acceleration of the amortization expense of finite-lived intangible assets, or the recognition of additional consideration which would be expensed.

Value of long-lived assets, including goodwill and other intangibles. We carry a variety of long-lived assets on our consolidated balance sheets including property and equipment, investments, identifiable intangible assets, and goodwill. We periodically review the carrying value of all of these assets based, in part, upon current estimated market values and our projections of anticipated future cash flows. We undertake this review (i) on an annual basis for assets such as goodwill and non-amortizing intangible assets and (ii) on a periodic basis for other long-lived assets when facts and circumstances suggest that cash flows related to those assets may be diminished.

Any impairment charge that we record reduces our earnings. The goodwill impairment test consists of a two-step process. The first step is the comparison of the fair value to the carrying value of the reporting unit to determine if the carrying value exceeds the fair value. The second step measures the amount of an impairment loss, and is only performed if the carrying value exceeds the fair value of the reporting unit. We perform the annual impairment assessment on the later of January 1 or the first day of each fiscal year. This same impairment test will be performed at other times during the course of the year should an event occur which suggests that the recoverability of goodwill should be reconsidered. Non-amortizing intangibles are also subject to an annual impairment test. The impairment test consists of a comparison of the fair value of the non-amortizing intangible asset with its carrying amount. If the carrying amount of a non-amortizing intangible asset exceeds its fair value, an impairment loss in an amount equal to that excess is recognized. In addition, we currently evaluate the remaining useful life of our non-amortizing intangible assets at least annually to determine whether events or circumstances continue to support an indefinite useful life. If events or circumstances indicate that the useful lives of non-amortizing intangible assets are no longer indefinite, the assets will be tested for impairment. These intangible assets will then be amortized prospectively over their estimated remaining useful life and accounted for in the same manner as other intangible assets that are subject to amortization.

Through fiscal year 2013, we conducted annual goodwill impairment assessments for our reporting units:

analytical sciences and laboratory services, diagnostics, life sciences technology and medical imaging. We completed the annual goodwill impairment test using measurement dates of January 1, 2013 and January 2, 2012, and concluded based on the first step of the process that there was no goodwill impairment. At January 1, 2013, the fair value exceeded the carrying value by more than 30.0% for each reporting unit. While we believe that our estimates of current value are reasonable, if actual results differ from the estimates and judgments used including such items as future cash flows and the volatility inherent in markets which we serve, impairment charges against the carrying value of those assets could be required in the future. As part of integrating our recent acquisitions, in fiscal year 2012, we decided that prospectively we would primarily focus on the PerkinElmer trade name.

Accordingly, we undertook a review of certain of our trade names within our portfolio as part of a realignment of our marketing strategy, which resulted in pre-tax impairment charges of $74.2 million in fiscal year 2012. We concluded that the impairment for trade names was not a triggering event for goodwill because the impairment occurred as a result of our decision to phase out certain trade names. We do not believe that our future cash flows will be significantly impacted by these changes. During fiscal year 2013, we recorded a charge of $6.7 million for the impairment of certain long-lived assets within our Human Health segment, as the carrying amounts of the long-lived assets were not recoverable and exceeded their fair value. We recorded a charge of $3.0 million for the impairment of intangible assets during fiscal year 2011 within our Human Health segment for the full impairment of license agreements that we no longer intend to use. These non-cash impairments of long-lived assets, including intangible assets, have been recorded as a separate component of operating expenses.

Employee compensation and benefits. We sponsor both funded and unfunded U.S. and non-U.S. defined benefit pension plans and other postretirement benefits. Retirement and postretirement benefit plans are a significant cost of doing business, and represent obligations that will be ultimately settled far in the future, and therefore are subject to estimation. Retirement and postretirement benefit plan expenses are allocated to cost of revenue, research and development, and selling, general and administrative expenses, in our consolidated statements of operations. We immediately recognize actuarial gains and losses in operating results in the year in which the gains and losses occur. Actuarial gains and losses are measured annually as of fiscal year end and accordingly will be recorded in the fourth quarter, unless we are required to perform an interim remeasurement.



Pages:     | 1 |   ...   | 16 | 17 || 19 | 20 |   ...   | 34 |


Similar works:

«Aus der Klinik für Psychiatrie und Psychotherapie Universitätsklinikum des Saarlandes, Homburg/Saar (Direktor: Univ. Prof. Dr. med. Matthias Riemenschneider) Visuelle erotische Reize, Testosteron und ereigniskorrelierte Potentiale Dissertation zur Erlangung des akademischen Grades eines Doktors der Theoretischen Medizin der Medizinischen Fakultät der Universität des Saarlandes vorgelegt von Dipl.-Psych. Sandra Denter geboren am 18.02.1971 in Landstuhl Inhaltsverzeichnis 1. ZUSAMMENFASSUNG /...»

«Master-Thesis Die Therapie der Lese-Rechtschreibstörung (LRS) – eine logopädische Aufgabe? Kriterien für eine sprachtherapeutische Intervention Verfasser/Verfasserin: Andrea Gütinger Matr. Nr.: 1064157 Universitätslehrgang: 2 Logopädie Anzahl der Wörter: 17.543 Abgabedatum: zur Erlangung der Bezeichnung des akademischen Grades Master of Science am Zentrum für Medizinische Spezialisierungen der Donau-Universität Krems Betreuerfachgutachter/in: Univ.-Prof. Dr. med. Sibylle Brosch...»

«Aus der 4. Medizinischen Abteilung Städtisches Klinikum München GmbH – Klinikum Harlaching Akademisches Lehrkrankenhaus der LUDWIG-MAXIMILIANS-UNIVERSITÄT MÜNCHEN Chefarzt: Prof. Dr. R. Hartenstein Eine retrospektive, multizentrische Kohortenstudie zum HIV-assoziierten Morbus Hodgkin Dissertation zum Erwerb des Doktorgrades der Medizin an der Medizinischen Fakultät der Ludwig-Maximilians-Universität München vorgelegt von Pamela Bofinger aus Wertheim Mit Genehmigung der medizinischen...»

«ENVISION BREWSTER HUDSON VALLEY PATTERN FOR PROGRESS FELLOWS CLASS 2013 Introduction The Village of Brewster, located in the northeastern corner of Putnam County, is a hidden gem with a very diverse community, it has all the ingredients and potential to become a vibrant Main Street and downtown. Based upon the existing conditions of the village, there appears to be a lack of vitality that one might see elsewhere in small communities throughout the Hudson Valley. Ranging from current, more...»

«Available online at www.scholarsresearchlibrary.com Scholars Research Library Der Pharmacia Lettre, 2014, 6 (5):172-187 (http://scholarsresearchlibrary.com/archive.html) ISSN 0975-5071 USA CODEN: DPLEB4 Anti-arthritic and in vivo antioxidant effect of Hibiscus rosa-sinensis in Freund’s complete adjuvant induced arthritis Divya Gaubaa, Arulmozhi Sinnathambia*, Subhash L. Bodhankara and Kakasaheb R. Mahadikb Department of Pharmacology, Bharati Vidyapeeth University, Poona College of Pharmacy,...»

«Jacobs University Bremen Wird alles, was Spaß macht, besteuert? Das Für und Wider einer Berücksichtigung von Eigenverantwortung bei der medizinischen Versorgung am Beispiel von Übergewicht und Adipositas. Lars Schwettmann Priorisierung in der Medizin FOR 655 Nr. 34 / 2012 FOR 655 Working Paper serves to disseminate the research results of work in progress prior to publication to encourage academic debate. Copyright remains with the authors. Campus Ring 1 28759 Bremen Germany...»

«About Carbon Monoxide The Case of the CO Leak: Solving the Mysteries of Carbon Monoxide Exposures By Thomas Greiner Carbon monoxide causes more deaths from poisoning annually than any other substance, but diagnosing its source eludes all but the best-trained contractors. Thomas H. Greiner dissects the various ways CO exposures happen, and how they are commonly misdiagnosed. A colorless, odorless, flavorless, nonirritating gas, carbon monoxide (CO) causes more poisoning deaths today than any...»

«Lucadou, W.v. (2002): Die Magie der Pseudomaschine, in: Wilfried Belschner, Joachim Galuska, Harald Walach, Edith Zundel (Hrg.): Transpersonale Forschung im Kontext. Oldenburg: Transpersonale Studien 5, Bibliotheksund Informationssystem der Universität Oldenburg 2002. Walter v. Lucadou Die Magie der Pseudomaschine Zusammenfassung In vielen Bereichen der (Komplementäroder Alternativ-) Medizin und Psychologie (vor allem bei Diagnostik und Therapie) aber auch in der Alltagstechnik spielen...»

«A. E WILDER SMI1 NATURWISSENSC KENNEN KEINE EVOLUTION Experimentelle und theoretische Einwände gegen die Evolutionstheorie DER AUTOR A. E.Wilder Smith studierte Naturwissenschaft an der Universität Oxford und doktorierte auf dem Gebiet der Organischen Chemie an der Universität Reading. Während einiger Jahre war er in der Krebsforschung an der Universität London tätig, darauf Forschungsleiter der Pharmazeutischen Abteilung einer Schweizer Firma. Während dieser Zeit (1955—1964) war er...»

«EPA/630/R-03/003F March 2005 Supplemental Guidance for Assessing Susceptibility from Early-Life Exposure to Carcinogens Risk Assessment Forum U.S. Environmental Protection Agency Washington, DC 20460 AUTHORS AND CONTRIBUTORS This document was prepared by a Technical Panel of the Risk Assessment Forum.AUTHORS Hugh Barton, National Health and Environmental Effects Research Laboratory, ORD Jim Cogliano, National Center for Environmental Assessment, ORD Michael P. Firestone, Office of Children's...»





 
<<  HOME   |    CONTACTS
2016 www.book.dislib.info - Free e-library - Books, dissertations, abstract

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.